Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 15, 04 December 2023
Open
Access | Article
An evaluation of chemotherapy, surgery and immunotherapy’s effectiveness in tackling pancreatic cancer
* Author to whom correspondence should be addressed.
Abstract
Statistics show that among malignant tumors, pancreatic cancer has the poorest prognosis. Cancer has a low likelihood of survival, and early cancer diagnosis is challenging. The major therapies currently used include surgery, chemotherapy, and radiation, although the outcomes are not optimal. Treatments for pancreatic cancer using immunotherapy now appear more promising because to developments in molecular biology. The primary pancreatic cancer treatments will be analyzed and evaluated in this study, and it will be concluded that immunotherapy is the most promising course of action. The usage of patient range, toxicity, and other side effects are some of the difficulties, although it is still in the research and development stage.
Keywords
Pancreatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor Drugs, CAR-T Cell Immune Therapy, PD-1/PD-L1
References
1. Yoo B, Jordan V C, Sheedy P, Billig A M, Ross A, Pantazopoulos P and Medarova Z (2019) “RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy”, Scientific Reports, vol. 9, no. 1, pp. 4712-4720.
2. Delahoussaye A M, Jaoude A J, Green M, Fujimoto T N, Molkentine J, Garcia G C J, Gay J P, Feng N, Marszalek J, Fowlkes N and Taniguchi C M (2022) Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model”, BMC cancer, Volume 22, Issue 1, pp. 174-184.
3. Xiong H Q, Carr K and Abbruzzese J L (2019) “Cytotoxic Chemotherapy for Pancreatic Cancer Advances to Date and Future Direction”, Drugs (New York, N.Y.), Vol. 66, Issue 8, pp. 1059 - 1072.
4. Shaw K, Thomas A S, Rosario V L, Sugahara K N, Schrope B A, Chabot J A, Genkinger J M, Kwon W and Kluger M D (2021) “Long-term quality of life and global health following pancreatic surgery for benign and malignant pathologies”, Surgery, Volume 170, Issue 3, pp. 917-924.
5. Zhang Y, Zhu S, Yuan Z, Li Q, Ding R, Bao X, Zhen T, Fu Z, Fu H, Xing K, Yuan H and Chen T (2020) “Risk factors and socio-economic burden in pancreatic ductal adenocarcinoma operation: a machine learning based analysis”, BMC cancer, Volume 20, Issue 1, pp. 1161-1172.
6. Mucileanu A and Chira R, Mircea P A (2021). “PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies”, Medicine and Pharmacy Reports, 94(4), 402-410.
7. DeSelm C J, Tano Z E, Varghese A M and Adusumilli P S (2017). CAR T‐cell therapy for pancreatic cancer. Journal of Surgical Oncology, 116(1), 63-74.
8. Kim M J, Chang H, Nam G, Ko Y, Kim S H, Roberts T M and Ryu J H (2021) “RNAi Based Approaches for Pancreatic Cancer Therapy”, Pharmaceutics. Vol. 13, no. 10, pp. 1638-1660.
9. Akce M, Zaidi M Y, Waller E K, El-Rayes B F and Lesinski G B (2018) The potential of CAR T cell therapy in pancreatic cancer. Frontiers in Immunology, 9, 2166-2166.
10. Bear A S and Vonderheide R H O’Hara M H (2020) “Challenges and Opportunities for Pancreatic Cancer Immunotherapy”, Cencer cell, Volume 38, Issue 6, pp. 788-802.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-193-3
- ISBN (Online)
- 978-1-83558-194-0
- Published Date
- 04 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/15/20240431
- Copyright
- 04 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited